



Syntheses and metabolism of selected antipsychotics


General synthesis of phenothiazine neuroleptics



Other approach to phenothiazine skeleton: synthesis of thioridazine




Metabolism of chlorpromazine




Original synthesis of haloperidol

Scheme 1. Original Synthesis of Haloperidol by Janssen Pharmaceutica in 1958




Metabolism of haloperidol




Probably responsible for Parkinson's syndrome

Figure 3. Structures of metabolites of haloperidol (2).


Synthesis of clozapine




Main metabolic pathways of clozapine




Synthesis of quetiapine




Sertindole synthesis




Other modification of sertindole synthesis



Synthesis of ziprasidone




Main metabolites of ziprasidone




* Denotes the position of ¹⁴C label

Fig. 1. Structures of ziprasidone and its major metabolites. TMT, thiol methyltransferase.


Some other metabolites of ziprasidone




Synthesis of risperidone




Main metabolic pathways of risperidone




Synthesis of paliperidone



Main metabolites of paliperidone




Synthesis of sulpiride




SCHEME 6.14 Synthesis of sulpiride.

Synthesis of levosulpiride




SCHEME 6.15 Synthesis of levosulpiride.

METABOLIC PATHWAY OF SULPIRIDE IN DOG



METABOLIC PATHWAY OF SULPIRIDE IN RAT



Synthesis of amisulpride




















Table 1. Summary of the Chemical Structures and Excretion Profiles of the Atypical Antipsychotics

Chemical Structure	Excretion
<p>Aripiprazole</p> 	 <p><1% 24-25% 18% 37% 20%</p> <p>urine unchanged urine changed feces unchanged feces changed unrecovered</p>
<p>Clozapine</p> 	 <p>0.3% 48.5% 2% 28% 21%</p> <p>urine unchanged urine changed feces unchanged feces changed unrecovered</p>
<p>Iloperidone</p> 	 <p><1% 57-58% <1% 19-20% 22%</p> <p>urine unchanged urine changed feces unchanged feces changed unrecovered</p>
<p>Olanzapine</p> 	 <p>7% 50% 2% 28% 13%</p> <p>urine unchanged urine changed feces unchanged feces changed unrecovered</p>
<p>Paliperidone</p> 	 <p>40% 20% 11% 9%</p> <p>urine unchanged urine changed feces unchanged feces changed unrecovered</p>
<p>Quetiapine</p> 	 <p><0.5% 72.5% 0.5% 19.5% 7%</p> <p>urine unchanged urine changed feces unchanged feces changed unrecovered</p>
<p>Risperidone</p> 	 <p>5% 65% 14% 16%</p> <p>urine unchanged urine changed feces unchanged feces changed unrecovered</p> <p>* Note: These excretion parameters are specific to patients who are extensive CYP2D6 metabolizers.</p>
<p>Ziprasidone</p> 	 <p><1% 19-20% <4% 63-67% 12%</p> <p>urine unchanged urine changed feces unchanged feces changed unrecovered</p>

The chemical structures of each of the 8 reviewed atypical antipsychotic agents are presented with a bar chart depicting the relationship between the excretory (i.e., urine or feces, changed or unchanged) profiles. These data highlight the magnitude of differences in the excretory profiles among the atypical antipsychotic agents.